News & Insights
FibriCheck proudly graduates from the TMCi accelerator, gaining clinical insights, U.S. market validation, and strategic partnerships to expand its digital health impact across the U.S.
FibriCheck hits 20 million heart rhythm measurements, highlighting global trust and a life-saving story that inspired the app’s creation and continued innovation.
FibriCheck partners with Midwest Cardiovascular Institute to bring FDA‑cleared smartphone AFib detection to their patients through remote monitoring via app.
FibriCheck teams up with Smart Meter to deliver clinically validated heart rhythm data to U.S. healthcare providers via remote patient monitoring solutions.
FibriCheck has joined the AARP® AgeTech Collaborative™, an 8-week accelerator program empowering innovative startups focused on healthy aging and heart health.
The Food and Drug Administration (FDA) cleared the FibriCheck application and portal for heart rhythm monitoring FibriCheck is now the only FDA-cleared smartphone application for heart rhythm monitoring with ECG equivalence in the U.S. FDA-clearance is an important stepping stone for FibriCheck’s further U.S. business development HASSELT - July 24, 2024 After a rigorous investigation procedure by the Food and Drug Administration, FibriCheck is now FDA-cleared (K232804). This is an important milestone which supports FibriCheck’s further development in the U.S. market. The FDA-clearance also allows FibriCheck to improve current U.S. care pathways and to provide millions of Americans with the ability to just use their smartphone to obtain easy and accurate heart rhythm measurements. These measurements can enable the early detection and monitoring of heart rhythm conditions such as atrial fibrillation.
